IL126548A - Pharmaceutical preparations that suppress the immune system containing aspirochlorine or its 9-chlorine derivative - Google Patents

Pharmaceutical preparations that suppress the immune system containing aspirochlorine or its 9-chlorine derivative

Info

Publication number: IL126548A
Authority: IL; Israel
Prior art keywords: compound; cells; formula; useful; immunosuppressive
Prior art date: 1996-05-03

Application number

IL12654897A

Other languages

English (en)

Hebrew (he)

Other versions

IL126548A0 (en

Original Assignee

Lepetit Spa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-05-03

Filing date

1997-04-23

Publication date

2002-02-10

1997-04-23 Application filed by Lepetit Spa filed Critical Lepetit Spa

1999-08-17 Publication of IL126548A0 publication Critical patent/IL126548A0/xx

2002-02-10 Publication of IL126548A publication Critical patent/IL126548A/en

Links

230000001506 immunosuppresive effect Effects 0.000 title claims abstract description 36
239000003814 drug Substances 0.000 title claims abstract description 20
HEXYWHYANGOMLJ-UHFFFAOYSA-N Aspirochlorine Natural products COC1c2cc(Cl)c(O)cc2OC13N4SSC(NC3=O)C4=O HEXYWHYANGOMLJ-UHFFFAOYSA-N 0.000 title description 25
XMFSSFONDVHNFO-AUTRQRHGSA-N Aspirochlorine Chemical compound N1C(=O)[C@]23OC4=CC(O)=C(Cl)C=C4[C@@H]3SS[C@H]1C(=O)N2OC XMFSSFONDVHNFO-AUTRQRHGSA-N 0.000 title description 19
150000001875 compounds Chemical class 0.000 claims abstract description 91
239000000460 chlorine Chemical group 0.000 claims abstract description 7
229910052801 chlorine Chemical group 0.000 claims abstract description 7
239000001257 hydrogen Substances 0.000 claims abstract description 7
229910052739 hydrogen Inorganic materials 0.000 claims abstract description 7
125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 6
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims abstract description 5
238000011282 treatment Methods 0.000 claims description 20
208000023275 Autoimmune disease Diseases 0.000 claims description 18
206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 8
201000006417 multiple sclerosis Diseases 0.000 claims description 8
206010039073 rheumatoid arthritis Diseases 0.000 claims description 8
208000035408 type 1 diabetes mellitus 1 Diseases 0.000 claims description 8
230000024932 T cell mediated immunity Effects 0.000 claims description 6
210000004027 cell Anatomy 0.000 description 40
210000001744 T-lymphocyte Anatomy 0.000 description 36
239000000427 antigen Substances 0.000 description 36
102000036639 antigens Human genes 0.000 description 36
108091007433 antigens Proteins 0.000 description 36
201000010099 disease Diseases 0.000 description 32
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 32
210000001519 tissue Anatomy 0.000 description 32
102000010789 Interleukin-2 Receptors Human genes 0.000 description 26
108010038453 Interleukin-2 Receptors Proteins 0.000 description 26
230000028993 immune response Effects 0.000 description 26
230000007246 mechanism Effects 0.000 description 20
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 18
239000000463 material Substances 0.000 description 16
238000002360 preparation method Methods 0.000 description 16
210000000987 immune system Anatomy 0.000 description 15
239000000203 mixture Substances 0.000 description 15
108010062580 Concanavalin A Proteins 0.000 description 14
239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 14
241001465754 Metazoa Species 0.000 description 14
230000000735 allogeneic effect Effects 0.000 description 14
230000021633 leukocyte mediated immunity Effects 0.000 description 14
210000000056 organ Anatomy 0.000 description 14
OZFAFGSSMRRTDW-UHFFFAOYSA-N (2,4-dichlorophenyl) benzenesulfonate Chemical compound ClC1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 OZFAFGSSMRRTDW-UHFFFAOYSA-N 0.000 description 12
230000009471 action Effects 0.000 description 12
210000004698 lymphocyte Anatomy 0.000 description 12
230000001404 mediated effect Effects 0.000 description 12
239000000243 solution Substances 0.000 description 12
239000000126 substance Substances 0.000 description 12
230000001629 suppression Effects 0.000 description 12
239000008194 pharmaceutical composition Substances 0.000 description 11
210000003719 b-lymphocyte Anatomy 0.000 description 10
210000002540 macrophage Anatomy 0.000 description 10
239000000546 pharmaceutical excipient Substances 0.000 description 10
241000894006 Bacteria Species 0.000 description 8
230000003044 adaptive effect Effects 0.000 description 8
230000000843 anti-fungal effect Effects 0.000 description 8
239000002775 capsule Substances 0.000 description 8
239000000470 constituent Substances 0.000 description 8
230000006378 damage Effects 0.000 description 8
239000000725 suspension Substances 0.000 description 8
230000000694 effects Effects 0.000 description 7
WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 6
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
230000033289 adaptive immune response Effects 0.000 description 6
NVCJFEMWTAVKAU-KWHPKRGUSA-N antibiotic a 30641 Chemical compound S1S[C@H]2C3=CC(Cl)=C(O)C=C3OC22C(=O)N(OC)[C@@H]1C(=O)N2 NVCJFEMWTAVKAU-KWHPKRGUSA-N 0.000 description 6
210000004369 blood Anatomy 0.000 description 6
239000008280 blood Substances 0.000 description 6
239000003795 chemical substances by application Substances 0.000 description 6
230000004154 complement system Effects 0.000 description 6
238000000855 fermentation Methods 0.000 description 6
230000004151 fermentation Effects 0.000 description 6
230000001900 immune effect Effects 0.000 description 6
239000003018 immunosuppressive agent Substances 0.000 description 6
229940125721 immunosuppressive agent Drugs 0.000 description 6
230000005764 inhibitory process Effects 0.000 description 6
210000000066 myeloid cell Anatomy 0.000 description 6
201000003068 rheumatic fever Diseases 0.000 description 6
239000006228 supernatant Substances 0.000 description 6
230000001225 therapeutic effect Effects 0.000 description 6
210000000224 granular leucocyte Anatomy 0.000 description 5
230000001105 regulatory effect Effects 0.000 description 5
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
206010020751 Hypersensitivity Diseases 0.000 description 4
102000000589 Interleukin-1 Human genes 0.000 description 4
108010002352 Interleukin-1 Proteins 0.000 description 4
102000000588 Interleukin-2 Human genes 0.000 description 4
108010002350 Interleukin-2 Proteins 0.000 description 4
241000124008 Mammalia Species 0.000 description 4
-1 PrimogelTM Polymers 0.000 description 4
239000012980 RPMI-1640 medium Substances 0.000 description 4
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
229930006000 Sucrose Natural products 0.000 description 4
241000700605 Viruses Species 0.000 description 4
239000004480 active ingredient Substances 0.000 description 4
230000004721 adaptive immunity Effects 0.000 description 4
239000002671 adjuvant Substances 0.000 description 4
230000000840 anti-viral effect Effects 0.000 description 4
230000000890 antigenic effect Effects 0.000 description 4
230000007123 defense Effects 0.000 description 4
239000000796 flavoring agent Substances 0.000 description 4
238000000684 flow cytometry Methods 0.000 description 4
GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 4
235000003599 food sweetener Nutrition 0.000 description 4
238000009472 formulation Methods 0.000 description 4
210000002865 immune cell Anatomy 0.000 description 4
230000036039 immunity Effects 0.000 description 4
230000002401 inhibitory effect Effects 0.000 description 4
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
239000002609 medium Substances 0.000 description 4
238000000034 method Methods 0.000 description 4
OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 4
LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 4
230000000813 microbial effect Effects 0.000 description 4
239000006187 pill Substances 0.000 description 4
229920001223 polyethylene glycol Polymers 0.000 description 4
102000004169 proteins and genes Human genes 0.000 description 4
108090000623 proteins and genes Proteins 0.000 description 4
230000004044 response Effects 0.000 description 4
239000000523 sample Substances 0.000 description 4
230000028327 secretion Effects 0.000 description 4
241000894007 species Species 0.000 description 4
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
239000005720 sucrose Substances 0.000 description 4
239000003765 sweetening agent Substances 0.000 description 4
239000006188 syrup Substances 0.000 description 4
235000020357 syrup Nutrition 0.000 description 4
239000003826 tablet Substances 0.000 description 4
SRVJKTDHMYAMHA-WUXMJOGZSA-N thioacetazone Chemical compound CC(=O)NC1=CC=C(\C=N\NC(N)=S)C=C1 SRVJKTDHMYAMHA-WUXMJOGZSA-N 0.000 description 4
DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 4
229940121375 antifungal agent Drugs 0.000 description 3
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
240000006439 Aspergillus oryzae Species 0.000 description 2
235000002247 Aspergillus oryzae Nutrition 0.000 description 2
241000134719 Aspergillus tamarii Species 0.000 description 2
241000416162 Astragalus gummifer Species 0.000 description 2
208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 2
108091003079 Bovine Serum Albumin Proteins 0.000 description 2
241000222122 Candida albicans Species 0.000 description 2
206010009900 Colitis ulcerative Diseases 0.000 description 2
229920002261 Corn starch Polymers 0.000 description 2
229930105110 Cyclosporin A Natural products 0.000 description 2
PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 2
108010036949 Cyclosporine Proteins 0.000 description 2
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
108010010803 Gelatin Proteins 0.000 description 2
206010018364 Glomerulonephritis Diseases 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
239000007995 HEPES buffer Substances 0.000 description 2
239000012981 Hank's balanced salt solution Substances 0.000 description 2
206010019799 Hepatitis viral Diseases 0.000 description 2
241000282412 Homo Species 0.000 description 2
102000004877 Insulin Human genes 0.000 description 2
108090001061 Insulin Proteins 0.000 description 2
102000008070 Interferon-gamma Human genes 0.000 description 2
108010074328 Interferon-gamma Proteins 0.000 description 2
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
229930182816 L-glutamine Natural products 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
102000008072 Lymphokines Human genes 0.000 description 2
108010074338 Lymphokines Proteins 0.000 description 2
102000018697 Membrane Proteins Human genes 0.000 description 2
108010052285 Membrane Proteins Proteins 0.000 description 2
244000246386 Mentha pulegium Species 0.000 description 2
235000016257 Mentha pulegium Nutrition 0.000 description 2
235000004357 Mentha x piperita Nutrition 0.000 description 2
229920000168 Microcrystalline cellulose Polymers 0.000 description 2
241000699666 Mus <mouse, genus> Species 0.000 description 2
241000699670 Mus sp. Species 0.000 description 2
229910019142 PO4 Inorganic materials 0.000 description 2
229930182555 Penicillin Natural products 0.000 description 2
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
239000002202 Polyethylene glycol Substances 0.000 description 2
239000004743 Polypropylene Substances 0.000 description 2
241000700159 Rattus Species 0.000 description 2
239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 2
229920001800 Shellac Polymers 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
229920001615 Tragacanth Polymers 0.000 description 2
201000006704 Ulcerative Colitis Diseases 0.000 description 2
150000001242 acetic acid derivatives Chemical class 0.000 description 2
230000004913 activation Effects 0.000 description 2
239000012190 activator Substances 0.000 description 2
230000006978 adaptation Effects 0.000 description 2
230000008649 adaptation response Effects 0.000 description 2
239000000783 alginic acid Substances 0.000 description 2
235000010443 alginic acid Nutrition 0.000 description 2
229920000615 alginic acid Polymers 0.000 description 2
229960001126 alginic acid Drugs 0.000 description 2
150000004781 alginic acids Chemical class 0.000 description 2
239000003708 ampul Substances 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
244000000054 animal parasite Species 0.000 description 2
239000003242 anti bacterial agent Substances 0.000 description 2
230000000845 anti-microbial effect Effects 0.000 description 2
230000000259 anti-tumor effect Effects 0.000 description 2
210000000612 antigen-presenting cell Anatomy 0.000 description 2
239000003963 antioxidant agent Substances 0.000 description 2
235000006708 antioxidants Nutrition 0.000 description 2
235000010323 ascorbic acid Nutrition 0.000 description 2
229960005070 ascorbic acid Drugs 0.000 description 2
239000011668 ascorbic acid Substances 0.000 description 2
230000001363 autoimmune Effects 0.000 description 2
230000006472 autoimmune response Effects 0.000 description 2
230000005784 autoimmunity Effects 0.000 description 2
230000001580 bacterial effect Effects 0.000 description 2
210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 2
235000019445 benzyl alcohol Nutrition 0.000 description 2
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
239000011230 binding agent Substances 0.000 description 2
230000003115 biocidal effect Effects 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
230000037396 body weight Effects 0.000 description 2
210000001185 bone marrow Anatomy 0.000 description 2
235000010633 broth Nutrition 0.000 description 2
239000000872 buffer Substances 0.000 description 2
229940095731 candida albicans Drugs 0.000 description 2
239000000969 carrier Substances 0.000 description 2
238000004113 cell culture Methods 0.000 description 2
239000002738 chelating agent Substances 0.000 description 2
238000001311 chemical methods and process Methods 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
235000015218 chewing gum Nutrition 0.000 description 2
125000001309 chloro group Chemical group Cl* 0.000 description 2
229960001265 ciclosporin Drugs 0.000 description 2
150000001860 citric acid derivatives Chemical class 0.000 description 2
238000000576 coating method Methods 0.000 description 2
229940075614 colloidal silicon dioxide Drugs 0.000 description 2
238000004040 coloring Methods 0.000 description 2
229940124301 concurrent medication Drugs 0.000 description 2
239000013068 control sample Substances 0.000 description 2
239000008120 corn starch Substances 0.000 description 2
230000006866 deterioration Effects 0.000 description 2
239000008121 dextrose Substances 0.000 description 2
239000003085 diluting agent Substances 0.000 description 2
239000003937 drug carrier Substances 0.000 description 2
239000000975 dye Substances 0.000 description 2
229960001484 edetic acid Drugs 0.000 description 2
239000002702 enteric coating Substances 0.000 description 2
238000009505 enteric coating Methods 0.000 description 2
239000010685 fatty oil Substances 0.000 description 2
239000012894 fetal calf serum Substances 0.000 description 2
235000019634 flavors Nutrition 0.000 description 2
235000013355 food flavoring agent Nutrition 0.000 description 2
229940044627 gamma-interferon Drugs 0.000 description 2
229920000159 gelatin Polymers 0.000 description 2
239000008273 gelatin Substances 0.000 description 2
239000007903 gelatin capsule Substances 0.000 description 2
235000019322 gelatine Nutrition 0.000 description 2
235000011852 gelatine desserts Nutrition 0.000 description 2
239000011521 glass Substances 0.000 description 2
235000011187 glycerol Nutrition 0.000 description 2
229910052736 halogen Inorganic materials 0.000 description 2
150000002367 halogens Chemical class 0.000 description 2
230000036541 health Effects 0.000 description 2
210000002443 helper t lymphocyte Anatomy 0.000 description 2
208000007475 hemolytic anemia Diseases 0.000 description 2
210000003630 histaminocyte Anatomy 0.000 description 2
235000001050 hortel pimenta Nutrition 0.000 description 2
210000005104 human peripheral blood lymphocyte Anatomy 0.000 description 2
230000028996 humoral immune response Effects 0.000 description 2
230000008105 immune reaction Effects 0.000 description 2
230000007233 immunological mechanism Effects 0.000 description 2
230000001771 impaired effect Effects 0.000 description 2
238000011534 incubation Methods 0.000 description 2
239000003701 inert diluent Substances 0.000 description 2
208000014674 injury Diseases 0.000 description 2
229940125396 insulin Drugs 0.000 description 2
230000003993 interaction Effects 0.000 description 2
210000004153 islets of langerhan Anatomy 0.000 description 2
238000009533 lab test Methods 0.000 description 2
239000008101 lactose Substances 0.000 description 2
239000007788 liquid Substances 0.000 description 2
239000011344 liquid material Substances 0.000 description 2
210000004185 liver Anatomy 0.000 description 2
239000000314 lubricant Substances 0.000 description 2
235000019359 magnesium stearate Nutrition 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
STZCRXQWRGQSJD-GEEYTBSJSA-M methyl orange Chemical compound [Na+].C1=CC(N(C)C)=CC=C1\N=N\C1=CC=C(S([O-])(=O)=O)C=C1 STZCRXQWRGQSJD-GEEYTBSJSA-M 0.000 description 2
229940012189 methyl orange Drugs 0.000 description 2
239000004292 methyl p-hydroxybenzoate Substances 0.000 description 2
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 2
229960001047 methyl salicylate Drugs 0.000 description 2
229960002216 methylparaben Drugs 0.000 description 2
244000005700 microbiome Species 0.000 description 2
229940016286 microcrystalline cellulose Drugs 0.000 description 2
235000019813 microcrystalline cellulose Nutrition 0.000 description 2
239000008108 microcrystalline cellulose Substances 0.000 description 2
206010028417 myasthenia gravis Diseases 0.000 description 2
210000004165 myocardium Anatomy 0.000 description 2
230000004719 natural immunity Effects 0.000 description 2
210000005036 nerve Anatomy 0.000 description 2
230000001537 neural effect Effects 0.000 description 2
231100000252 nontoxic Toxicity 0.000 description 2
230000003000 nontoxic effect Effects 0.000 description 2
239000000346 nonvolatile oil Substances 0.000 description 2
239000008188 pellet Substances 0.000 description 2
229940049954 penicillin Drugs 0.000 description 2
210000005105 peripheral blood lymphocyte Anatomy 0.000 description 2
235000021317 phosphate Nutrition 0.000 description 2
150000003013 phosphoric acid derivatives Chemical class 0.000 description 2
239000004033 plastic Substances 0.000 description 2
229920003023 plastic Polymers 0.000 description 2
229920001155 polypropylene Polymers 0.000 description 2
229920001282 polysaccharide Polymers 0.000 description 2
239000005017 polysaccharide Substances 0.000 description 2
150000004804 polysaccharides Chemical class 0.000 description 2
239000003755 preservative agent Substances 0.000 description 2
230000035755 proliferation Effects 0.000 description 2
238000011321 prophylaxis Methods 0.000 description 2
230000036647 reaction Effects 0.000 description 2
CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 2
229940081974 saccharin Drugs 0.000 description 2
235000019204 saccharin Nutrition 0.000 description 2
239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 2
239000012056 semi-solid material Substances 0.000 description 2
239000004208 shellac Substances 0.000 description 2
229940113147 shellac Drugs 0.000 description 2
ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 2
235000013874 shellac Nutrition 0.000 description 2
ZEYOIOAKZLALAP-UHFFFAOYSA-M sodium amidotrizoate Chemical compound [Na+].CC(=O)NC1=C(I)C(NC(C)=O)=C(I)C(C([O-])=O)=C1I ZEYOIOAKZLALAP-UHFFFAOYSA-M 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
239000001509 sodium citrate Substances 0.000 description 2
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
235000010267 sodium hydrogen sulphite Nutrition 0.000 description 2
239000011343 solid material Substances 0.000 description 2
239000002904 solvent Substances 0.000 description 2
238000010186 staining Methods 0.000 description 2
239000008107 starch Substances 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
229960005322 streptomycin Drugs 0.000 description 2
239000000829 suppository Substances 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
201000000596 systemic lupus erythematosus Diseases 0.000 description 2
206010043778 thyroiditis Diseases 0.000 description 2
230000000451 tissue damage Effects 0.000 description 2
231100000827 tissue damage Toxicity 0.000 description 2
230000008733 trauma Effects 0.000 description 2
239000003981 vehicle Substances 0.000 description 2
201000001862 viral hepatitis Diseases 0.000 description 2
235000012431 wafers Nutrition 0.000 description 2
238000005406 washing Methods 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
239000008215 water for injection Substances 0.000 description 2
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
239000005022 packaging material Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Epidemiology (AREA)
Diabetes (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Emergency Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Pain & Pain Management (AREA)
Hematology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Obesity (AREA)
Endocrinology (AREA)
Transplantation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

IL12654897A 1996-05-03 1997-04-23 Pharmaceutical preparations that suppress the immune system containing aspirochlorine or its 9-chlorine derivative IL126548A (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP96106991		1996-05-03
PCT/EP1997/002049 WO1997041862A1 (en)	1996-05-03	1997-04-23	Use of aspirochlorine or derivatives thereof as immunosuppressive agents

Publications (2)

Publication Number	Publication Date
IL126548A0 IL126548A0 (en)	1999-08-17
IL126548A true IL126548A (en)	2002-02-10

Family

ID=8222742

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL12654897A IL126548A (en)	1996-05-03	1997-04-23	Pharmaceutical preparations that suppress the immune system containing aspirochlorine or its 9-chlorine derivative

Country Status (13)

Country	Link
US (1)	US6133254A (de)
EP (1)	EP0914129B1 (de)
JP (1)	JP4287908B2 (de)
KR (1)	KR100439928B1 (de)
AT (1)	ATE209493T1 (de)
AU (1)	AU705290B2 (de)
CA (1)	CA2253635C (de)
DE (1)	DE69708645T2 (de)
DK (1)	DK0914129T3 (de)
ES (1)	ES2163763T3 (de)
IL (1)	IL126548A (de)
PT (1)	PT914129E (de)
WO (1)	WO1997041862A1 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2007287928A (ja)	2006-04-17	2007-11-01	Nec Electronics Corp	半導体集積回路およびその製造方法ならびにマスク

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3991052A (en) *	1975-07-18	1976-11-09	Eli Lilly And Company	Antibiotic A-30641
US4001086A (en) *	1975-07-18	1977-01-04	Eli Lilly And Company	Antibiotic a-30641 and process for production thereof
JP3383718B2 (ja) *	1995-02-15	2003-03-04	ニチモウ株式会社	大豆蛋白を原料とした生成物の製造方法

1997
- 1997-04-23 PT PT97921706T patent/PT914129E/pt unknown
- 1997-04-23 DE DE69708645T patent/DE69708645T2/de not_active Expired - Lifetime
- 1997-04-23 JP JP53947397A patent/JP4287908B2/ja not_active Expired - Lifetime
- 1997-04-23 US US09/171,848 patent/US6133254A/en not_active Expired - Lifetime
- 1997-04-23 AT AT97921706T patent/ATE209493T1/de active
- 1997-04-23 DK DK97921706T patent/DK0914129T3/da active
- 1997-04-23 AU AU27684/97A patent/AU705290B2/en not_active Expired
- 1997-04-23 IL IL12654897A patent/IL126548A/en not_active IP Right Cessation
- 1997-04-23 KR KR10-1998-0708829A patent/KR100439928B1/ko not_active Expired - Lifetime
- 1997-04-23 WO PCT/EP1997/002049 patent/WO1997041862A1/en not_active Ceased
- 1997-04-23 EP EP97921706A patent/EP0914129B1/de not_active Expired - Lifetime
- 1997-04-23 ES ES97921706T patent/ES2163763T3/es not_active Expired - Lifetime
- 1997-04-23 CA CA002253635A patent/CA2253635C/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
AU2768497A (en)	1997-11-26
WO1997041862A1 (en)	1997-11-13
CA2253635C (en)	2006-01-03
DK0914129T3 (da)	2002-01-28
EP0914129A1 (de)	1999-05-12
ATE209493T1 (de)	2001-12-15
US6133254A (en)	2000-10-17
JP2000514403A (ja)	2000-10-31
ES2163763T3 (es)	2002-02-01
AU705290B2 (en)	1999-05-20
EP0914129B1 (de)	2001-11-28
KR100439928B1 (ko)	2004-12-16
KR20000010724A (ko)	2000-02-25
PT914129E (pt)	2002-04-29
DE69708645D1 (de)	2002-01-10
JP4287908B2 (ja)	2009-07-01
DE69708645T2 (de)	2002-08-08
IL126548A0 (en)	1999-08-17
CA2253635A1 (en)	1997-11-13

Legal Events

Date	Code	Title
2002-06-30	FF	Patent granted
2002-08-14	KB	Patent renewed
2003-07-06	KB	Patent renewed
2007-07-06	KB	Patent renewed
2011-04-28	KB	Patent renewed
2015-03-31	KB	Patent renewed
2017-11-30	EXP	Patent expired

Publication	Publication Date	Title
Sullivan	2004	Graft-vs-host disease
Kim et al.	1989	Infection and cyclosporine
US20090054358A1 (en)	2009-02-26	Flt3 inhibitors for immune suppression
JP2005517637A (ja)	2005-06-16	体外フォトフォレーシスおよび／またはアポプトーシス細胞による一定の被験体を前処理するための方法
NO179908B (no)	1996-09-30	Analogifremgangsmåte for fremstilling av terapeutisk aktive, carbocykliske adenosinanaloger
Minagawa et al.	1987	Experimental allergic encephalomyelitis in the Lewis rat: a model of predictable relapse by cyclophosphamide
Buurman et al.	1986	Cyclosporin A inhibits IL 2-driven proliferation of human alloactivated T cells.
US6133254A (en)	2000-10-17	Use of aspirochlorine or derivatives thereof as immunosuppressive agents
Finelli et al.	1976	Recurrent aseptic meningitis in an elderly man: unusual prodrome of systemic lupus erythematosus
Chen et al.	1998	Chronically HIV-1-infected monocytic cells induce apoptosis in cocultured T cells
EP0956025B1 (de)	2005-01-05	Verfahren zur immununterdrückung
Algros et al.	2002	Danger of systemic cyclosporine for corneal graft
CA2044328A1 (en)	1991-12-15	Efomycins a.e. and g as antiinflammatory agents
Bell et al.	1987	Characterization of a cell population in thoracic duct lymph that adoptively transfers rejection of adult Trichinella spiralis to normal rats
SA109300384B1 (ar)	2013-04-20	مشتقات 5-(4- ميثان سلفونيل-فينيل)- ثيازول لعلاج الأمراض الالتهابية الحادة والمزمنة
NO305207B1 (no)	1999-04-19	Nye trans-syklopentanylpurinanaloger som er anvendbare som immunoundertrykkende midler
KR910004868B1 (ko)	1991-07-15	인체 단일 클론항체 및 그것을 활성성분으로 함유하는 감염증의 예방 및 치료용 약학적 제제
US5453431A (en)	1995-09-26	Use of hydroxychloroquine for treatment of graft-versus-host disease
AU642526B2 (en)	1993-10-21	Method of immunosuppression using cyclopentenyl substituted nucleoside analogs and compositions thereof
Crow	1985	Enhancement of the impaired autologous mixed leukocyte reaction in patients with systemic lupus erythematosus.
JP3817273B2 (ja)	2006-09-06	免疫抑制治療、抗ガン治療および抗ウイルス治療用の薬学的組成物
CN116744913A (zh)	2023-09-12	包含苯衍生物作为免疫抑制剂的免疫抑制药物组合物
US5962511A (en)	1999-10-05	Drugs for allergic and eosinophilic diseases
Marcus et al.	1981	In vitro studies in reproductive immunology, 3. Restoration of mitogenic activity of lymphocytes inhibited by seminal plasma in man
CN120241739A (zh)	2025-07-04	Menin抑制剂BN104在制备预防和治疗移植物抗宿主病的应用